MANNKIND CORP Deferred Income Tax Expense (Benefit)
MANNKIND CORP (MNKD) reported Deferred Income Tax Expense (Benefit) of -$19.47 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-26
- MANNKIND CORP deferred income tax expense (benefit) for fiscal 2025 was -$19.47M, a 602.50% decline from fiscal 2024.
- MANNKIND CORP deferred income tax expense (benefit) for fiscal 2024 was $3.87M, a 43.13% decline from fiscal 2023.
- MANNKIND CORP deferred income tax expense (benefit) for fiscal 2023 was $6.81M.
- MANNKIND CORP deferred income tax expense (benefit) for fiscal 2022 was -$9.94M.
| Period end | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$19.47M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $3.87M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $6.81M 10-K · filed 2026-02-26 | |
| 2022-12-31 | -$9.94M 10-K · filed 2025-02-26 | |
| 2021-12-31 | -$19.63M 10-K · filed 2024-02-27 | |
| 2020-12-31 | -$4.85M 10-K · filed 2023-02-23 | |
| 2019-12-31 | -$5.25M 10-K · filed 2021-02-25 | |
| 2018-12-31 | -$11.07M 10-K · filed 2020-02-25 | $11.07M 10-K · filed 2019-02-26 |
| 2017-12-31 | -$260.20M 10-K · filed 2019-02-26 | |
| 2016-12-31 | $48.13M 10-K · filed 2019-02-26 | |
| 2015-12-31 | -$80.12M 10-K · filed 2018-02-27 | $0.00 10-K · filed 2016-03-15 |
| 2014-12-31 | -$65.50M 10-K · filed 2017-03-16 | $0.00 10-K · filed 2015-03-02 |
| 2013-12-31 | $0.00 10-K · filed 2016-03-15 | |
| 2012-12-31 | $0.00 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |